{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:34:37Z","timestamp":1782311677925,"version":"3.54.5"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"Background<\/jats:title>Primary Osteoporosis (POP) is a global public health issue, and traditional medications have long-term safety concerns. Epimedium, a kidney-tonifying traditional Chinese medicine (TCM), has the potential to regulate bone metabolism through multiple targets, but clinical evidence is scattered and inconclusive.<\/jats:p><\/jats:sec>Objective<\/jats:title>This systematic review and meta-analysis aim to evaluate the efficacy and safety of Epimedium and its active components in treating POP.<\/jats:p><\/jats:sec>Method<\/jats:title>Computer searches were conducted in multiple domestic and international databases, including PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), and Wanfang Database, to collect randomized controlled trials (RCTs) comparing the use of Epimedium as an adjunct or alternative therapy with traditional drug treatments for POP. Literature was screened according to predefined inclusion and exclusion criteria, quality assessments were performed on eligible articles, relevant data were extracted, and statistical analysis was conducted using RevMan 5.4 software.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 10 RCTs were included, with a final inclusion of 890 cases, 448 in the experimental group and 442 in the control group. Meta-analysis suggests that the overall efficacy rate of the Epimedium group was significantly higher than that of the control group (OR\u202f=\u202f3.80; 95% CI: 2.27,6.37; p<\/jats:italic>\u202f=\u202f0.0001). Compared with the control group, Epimedium group\u2019s Lumbar vertebra bone mineral density (BMD) (SMD\u202f=\u202f1.15; 95% CI: 0.61,1.70; p<\/jats:italic>\u202f&lt;\u202f0.0001), Femoral neck BMD (SMD\u202f=\u202f1.11; 95% CI: 0.58,1.65; p<\/jats:italic>\u202f&lt;\u202f0.0001), Distal radius BMD (SMD\u202f=\u202f1.27; 95% CI: 0.57,1.98; p<\/jats:italic>\u202f=\u202f0.0004), and Metacarpal BMD (MD\u202f=\u202f0.04; 95% CI: 0.04,0.12; p<\/jats:italic>\u202f&lt;\u202f0.0001) all showed significant improvement, with a shorter time to relief of lower back pain (MD\u202f=\u202f-11.38; 95% CI: \u221212.63, \u221210.12; p<\/jats:italic>\u202f&lt;\u202f0.00001). Serum alkaline phosphatase (ALP) was significantly reduced (MD\u202f=\u202f-8.78; 95% CI: \u221212.80, \u22124.77; &lt;0.0001), while bone-specific alkaline phosphatase (BALP) increased (MD\u202f=\u202f6.73; 95% CI: 3.32,10.14; p<\/jats:italic>\u202f=\u202f0.0001). Adverse reactions were low, mainly mild gastrointestinal reactions or skin allergies.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Epimedium can effectively improve bone density and clinical symptoms in patients with POP, with good safety, making it a potential alternative or adjunctive treatment option, but more high-quality studies are needed to verify long-term efficacy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1675160","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:27:59Z","timestamp":1758259679000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["The efficacy and safety of Epimedium in the treatment of primary osteoporosis: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xian-Quan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Hui","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-Jia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Ren","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ren","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3969\/j.issn.1674-2591.2022.06.001","article-title":"Osteoporosis and bone mineral diseases branch of the Chinese medical association. Diagnosis and treatment guidelines for primary osteoporosis (2022)","volume":"26","author":"Zhang","year":"2023","journal-title":"Chin Gen Pract."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3969\/j.issn.1671-0223(s).2024.16.024","article-title":"Epidemiological research and prevention and treatment strategies of primary osteoporosis","volume":"24","author":"Botege","year":"2024","journal-title":"Health Care Today."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the international osteoporosis foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch Osteoporos"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.12122\/j.issn.1673-4254.2025.03.01","article-title":"Epidemiological investigation of osteoporosis in Beijing area in the past 10 years: analysis of bone mineral density examination results of 30,599 Han people in a single center by dual-energy X-ray absorptiometry","volume":"45","author":"Zhou","year":"2025","journal-title":"J South Med Univ."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11657-022-01079-9","article-title":"The pattern and trends of disease burden due to low bone mineral density from 1990 to 2019\u202fin China: findings from the global burden of disease study 2019","volume":"17","author":"Chen","year":"2022","journal-title":"Arch Osteoporos."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/s0749-0690(02)00022-8","article-title":"Osteoporosis in elderly: prevention and treatment","volume":"18","author":"Srivastava","year":"2002","journal-title":"Clin Geriatr Med."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"673","DOI":"10.12056\/j.issn.1006-2785.2024.46.7.2024-407","article-title":"Progress in drug treatment of primary osteoporosis","volume":"24","author":"Wang","year":"2021","journal-title":"Zhejiang Med J."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3969\/j.issn.1674-4985.2024.11.039","article-title":"Research and progress of bisphosphonate drug-related osteonecrosia of the jawbone","volume":"21","author":"Liang","year":"2024","journal-title":"Med Innov China."},{"key":"ref9","article-title":"Reginster JYScientific advisory board of the European society for clinical and economic aspects of osteoporosis (ESCEO) and the committees of scientific advisors and national societies of the international osteoporosis foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume-title":"Osteoporos Int.","author":"Kanis","year":"2019"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.7539\/j.issn.1672-2981.2025.02.019","article-title":"Epimedium glycosides promote the proliferation and differentiation of MC3T3-E1 cells through the PI3K\/AKT signaling pathway","volume":"23","author":"Fan","year":"2025","journal-title":"Cent S Univ Pharm."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.11656\/j.issn.1673-9043.2022.04.22","article-title":"Research progress on the related pathways of icariin in the treatment of osteoporosis","volume":"41","author":"Zhang","year":"2022","journal-title":"J Tianjin Univ Tradit Chin Med."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13018-019-1307-6","article-title":"Icariin alleviates osteoarthritis by inhibiting NLRP3-mediated pyroptosis","volume":"14","author":"Zu","year":"2019","journal-title":"J Orthop Surg Res."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.3969\/j.issn.1006-2238.2022.10.012","article-title":"Study on the inhibition of osteoclast differentiation and bone resorption by icariin through estrogen receptor","volume":"57","author":"Gan","year":"2022","journal-title":"Jiangxi Med J."},{"key":"ref14","first-page":"149","article-title":"The mechanism of Epimedium glycosides protecting osteoporosis in ovariectomized rats through autophagy and apoptosis pathways","volume-title":"New Tradit Chin Med Drugs Clin Pharmacol","author":"He","year":"2023"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"ref16","first-page":"2191","article-title":"Effects of epimedium total flavonoids on bone mineral density and bone metabolism-related indices in primary osteoporosis","volume":"13","author":"Shou","year":"2009","journal-title":"J Clin Rehabil Tissue Eng Res."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1359\/jbmr.070405","article-title":"Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial","volume":"22","author":"Zhang","year":"2007","journal-title":"J Bone Miner Res."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"153680","DOI":"10.1016\/j.phymed.2021.153680","article-title":"Randomized, double-blind, placebo-controlled trial to examine the safety, pharmacokinetics and effects of Epimedium prenylflavonoids, on bone specific alkaline phosphatase and the osteoclast adaptor protein TRAF6\u202fin post-menopausal women","volume":"91","author":"Yong","year":"2021","journal-title":"Phytomedicine."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.16368\/j.issn.1674-8999.2017.10.520","article-title":"Clinical study on the treatment of primary osteoporosis with compound Epimedium oral liquid","volume":"32","author":"Tu","year":"2017","journal-title":"J Chin Med."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3969\/j.issn.1008-8849.2003.09.015","article-title":"Clinical effect evaluation of Epimedium macrocarpon in the prevention and treatment of osteoporosis","volume":"9","author":"Zhao","year":"2003","journal-title":"J Integr Tradit Chin West Med."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.3969\/j.issn.1009-6469.2018.09.047","article-title":"Clinical effect observation of epimedium combined with Danshen Kang bone capsules in the treatment of senile osteoporosis","volume":"22","author":"Tu","year":"2018","journal-title":"Anhui Yi Ke Da Xue Xue Bao."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3969\/j.issn.1002-7386.2014.02.007","article-title":"Clinical observation of treating senile osteoporosis with epimedium and calcium d","volume":"36","author":"Zhu","year":"2014","journal-title":"Hebei Yi Xue."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"101","DOI":"10.15887\/j.cnki.13-1389\/r.2017.09.049","article-title":"Clinical efficacy of Epimedium in the treatment of osteoporosis","volume":"10","author":"Zeng","year":"2017","journal-title":"J Ration Clin Drug Use."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.7501\/j.issn.1674-5515.2024.11.027","article-title":"Clinical study on the combined use of Epimedium total flavonoid capsules and alendronate for treating primary osteoporosis (kidney yang deficiency syndrome)","volume":"39","author":"Zhou","year":"2024","journal-title":"Mod Drugs Clin."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.16040\/j.cnki.cn15-1101.2019.01.012","article-title":"Clinical observation of Chinese medicine Epimedium to treat osteoporosis","volume":"38","author":"Liu","year":"2019","journal-title":"Inner Mongolia Tradit Chin Med."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.19664\/j.cnki.1002-2392.220262","article-title":"Advances in the study of the pharmacological effects of Epimedium","volume":"50","author":"Zhou","year":"2022","journal-title":"J Tradit Chin Med."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.13312\/j.issn.1671-7783.y210086","article-title":"Epimedium glycoside intervention research progress of osteoporosis","volume":"32","author":"Lv","year":"2022","journal-title":"J Jiangsu Univ."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3969\/j.issn.1006-7108.2019.05.027","article-title":"Research progress on the treatment of glucocorticoid induced osteoporosis with Epimedium brevicornum and its compound preparations","volume":"25","author":"Wan","year":"2019","journal-title":"Chin J Osteoporos."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3969\/j.issn.1006-7108.2020.07.017","article-title":"The value of bone mineral density in risk assessment of hip osteoporotic fracture","volume":"26","author":"Li","year":"2020","journal-title":"Chin J Osteoporos."},{"key":"ref30","first-page":"1772","article-title":"The active monomer components of Epimedium regulate the osteoporosis-related signaling pathways and affect the homeostasis of bone resorption and bone formation","volume":"26","author":"Li","year":"2022","journal-title":"Zhongguo Zuzhi Gongcheng Yanjiu."},{"key":"ref31","first-page":"780","article-title":"Molecular mechanism of icariin regulating osteogenic signal-related pathways in the treatment of steroid-induced avascular necrosis of the femoral head","volume":"26","author":"Li","year":"2022","journal-title":"Zhongguo zu zhi gong cheng yan jiu."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.12287\/j.issn.2096-8965.20210113","article-title":"Research progress on the mechanism of icariin promoting fracture healing","volume":"2","author":"Hou","year":"2021","journal-title":"Biomed Transl Sci."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3974","DOI":"10.3969\/j.issn.2095-4344.2083","article-title":"Osteogenesis of bone marrow mesenchymal stem cells on the icariin\/hydroxyapatite\/polylactic acid-glycolic acid copolymer scaffold","volume":"24","author":"Wang","year":"2020","journal-title":"Zhongguo Zu Zhi Gong Cheng Yan Jiu."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.19378\/j.issn.1003-9783.2024.03.012","article-title":"Safety evaluation of hypoglycemic components in Epimedium breviscapus and pharmacokinetic study of its five main components","volume":"35","author":"Lin","year":"2024","journal-title":"Tradit Chin Med New Drug Clin Pharmacol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"219","DOI":"10.11656\/j.issn.1673-9043.2019.03.04","article-title":"Progress in chemical composition analysis and pharmacokinetics of Epimedium brevicornum","volume":"38","author":"OuYang","year":"2019","journal-title":"J Tianjin Univ Tradit Chin Med."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijom.2016.10.009","article-title":"Efficacy of the c-terminal telopeptide test in predicting the development of bisphosphonate-related osteonecrosis of the jaw: a systematic review","volume":"46","author":"Dal Pr\u00e1","year":"2017","journal-title":"Int J Oral Maxillofac Surg."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"941","DOI":"10.17219\/acem\/174078","article-title":"Icariin ameliorates osteoporosis by activating autophagy in ovariectomized rats","volume":"33","author":"Zou","year":"2024","journal-title":"Adv Clin Exp Med."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3969\/j.issn.1006-7108.2020.06.001","article-title":"Expert consensus on the clinical application of biochemical indicators of bone metabolism (revised edition 2023)","volume":"1","author":"Zhang","year":"2023","journal-title":"Chin J Osteoporos."},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.26988\/d.cnki.gcdzu.2021.000375","article-title":"Study on the immunodiversity susceptibility components and mechanisms of Epimedium brevicornum-induced liver injury based on NLRP3 inflammasome","author":"Wang","year":"2021","journal-title":"Chengdu University of Traditional Chinese Medicine"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1080\/08923973.2024.2424293","article-title":"An integrative lipidomics and transcriptomics study revealing Bavachin and icariin synergistically induce idiosyncratic liver injury","volume":"46","author":"Li","year":"2024","journal-title":"Immunopharmacol Immunotoxicol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1675160\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T05:28:19Z","timestamp":1758259699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1675160\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":40,"alternative-id":["10.3389\/fmed.2025.1675160"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1675160","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"article-number":"1675160"}}